| Therapeutic | Bintrafusp |
| Target | PDL1/CD274 |
| Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS |
| Light Chain | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL |
| 100% seqID Fv Structure | 4nki [Fvs: HL], 5grj [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4nki [Fvs: HL] |
| 100% seqID Structure | 5grj [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb Fusion |
| Isotype | G1 |
| Highest Clinical Trial (Aug '24) | Approved |
| Estimated Status (Aug '24) | Active |
| Recorded Developmental Technology | Human Phage Display |
| INN Year Proposed | 2015 |
| INN Year Recommended | 2016 |
| Companies Involved | AIO Studien gGmbH, Array BioPharma, Chong Kun Dang, Dana-Farber Cancer Institute, Debiopharm, eFFECTOR Therapeutics, EMD Serono, Forty Seven, Fred Hutchinson Cancer Research Center, Gachon University Gil Medical Center, Hellenic Cooperative Oncology Group, Hospices Civils de Lyon, Johannes Gutenberg-University Mainz, M. D. Anderson Cancer Center, Merck KGaA, National Cancer Institute (USA), National Cancer Institute Slovakia, Netherlands Cancer Institute, Pfizer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Syndax Pharmaceuticals, Transgene, University College London, University of Birmingham, University of California San Diego, University of Iowa, Vaccinex, Vanderbilt-Ingram Cancer Center, VAXIMM, Verastem Oncology, Washington University School of Medicine |
| Conditions Approved | Merkel cell carcinoma, Urogenital cancer |
| Conditions Active | Renal cell carcinoma, Breast cancer, Diffuse large B cell lymphoma, Gastric cancer, Head and neck cancer, Non-small cell lung cancer, Ovarian cancer, Bladder cancer, Endometrial cancer, Fallopian tube cancer, Germ cell and embryonal neoplasms, Gestational trophoblastic disease, Glioblastoma, Haemangiosarcoma, Intestinal cancer, Leiomyosarcoma, Nasopharyngeal cancer, Neuroendocrine tumours, Osteosarcoma, Peripheral T-cell lymphoma, Peritoneal cancer, Prostate cancer, Recurrent respiratory papillomatosis, Small cell lung cancer, Solid tumours, Squamous cell cancer, Thymoma, Liposarcoma, Lymphoma, Oropharyngeal cancer, Pancreatic cancer, Acute myeloid leukaemia, Follicular lymphoma, Hodgkin's disease, Liver cancer, Meningioma |
| Conditions Discontinued | na |
| Notes | Avelumab and Bintrafusp have identical V domains |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
